{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T06:09:25Z","timestamp":1772777365058,"version":"3.50.1"},"reference-count":46,"publisher":"American Society of Hematology","issue":"20","license":[{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,22]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Besides many other mutations in known cancer driver genes, mantle cell lymphoma (MCL) is characterized by recurrent genetic alterations of important regulators of the phosphoinositol-3-kinase (PI3K) cascade including PIK3CA gains and PTEN losses. To evaluate the biological and functional consequences of these aberrations in MCL, we have introduced transgenic expression of PIK3CA (PIK3CA UP) and performed knockout\/knockdown of PTEN gene (PTEN KO\/KD) in 5 MCL cell lines. The modified cell lines were tested for associated phenotypes including dependence on upstream B-cell receptor (BCR) signaling (by an additional BCR knockout). PIK3CA overexpression decreased the dependence of the tested MCL on prosurvival signaling from BCR, decreased levels of oxidative phosphorylation, and increased resistance to 2-deoxy-glucose, a glycolysis inhibitor. Unchanged protein kinase B (AKT) phosphorylation status and unchanged sensitivity to a battery of PI3K inhibitors suggested that PIK3CA gain might affect MCL cells in AKT-independent manner. PTEN KO was associated with a more distinct phenotype: AKT hyperphosphorylation and overactivation, increased resistance to multiple inhibitors (most\u00a0of the tested PI3K inhibitors, Bruton tyrosine kinase inhibitor ibrutinib, and BCL2 inhibitor venetoclax), increased glycolytic rates with resistance to 2-deoxy-glucose, and significantly decreased dependence on prosurvival BCR signaling. Our results suggest that the frequent aberrations of the PI3K pathway may rewire associated signaling with lower dependence on BCR signaling, better metabolic and hypoxic adaptation, and targeted therapy resistance in MCL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013205","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T07:22:53Z","timestamp":1724052173000},"page":"5279-5289","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Impact of\n                    <i>PIK3CA<\/i>\n                    gain and PTEN loss on mantle cell lymphoma biology and sensitivity to targeted therapies"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4286-3538","authenticated-orcid":false,"given":"Nardjas","family":"Bettazova","sequence":"first","affiliation":[{"name":"1Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic"},{"name":"2Department of Medical Genetics, Third Faculty of Medicine, Charles University, Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5661-4456","authenticated-orcid":false,"given":"Jana","family":"Senavova","sequence":"additional","affiliation":[{"name":"3First Department of Medicine-Department of Hematology, Charles University General Hospital, Prague, Czech Republic"},{"name":"4BIOCEV LF1- Biotechnology and Biomedicine Centre, First Faculty of Medicine, Charles University, Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4913-9877","authenticated-orcid":false,"given":"Kristyna","family":"Kupcova","sequence":"additional","affiliation":[{"name":"3First Department of Medicine-Department of Hematology, Charles University General Hospital, Prague, Czech Republic"},{"name":"4BIOCEV LF1- Biotechnology and Biomedicine Centre, First Faculty of Medicine, Charles University, Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8701-5912","authenticated-orcid":false,"given":"Dana","family":"Sovilj","sequence":"additional","affiliation":[{"name":"5Institute of Biotechnology BIOCEV, Czech Academy of Sciences, Prague, Czech Republic"},{"name":"6Institute of Molecular Genetics, Czech Academy of Sciences, Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4629-4832","authenticated-orcid":false,"given":"Anezka","family":"Rajmonova","sequence":"additional","affiliation":[{"name":"4BIOCEV LF1- Biotechnology and Biomedicine Centre, First Faculty of Medicine, Charles University, Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ladislav","family":"Andera","sequence":"additional","affiliation":[{"name":"5Institute of Biotechnology BIOCEV, Czech Academy of Sciences, Prague, Czech Republic"},{"name":"6Institute of Molecular Genetics, Czech Academy of Sciences, Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6757-1332","authenticated-orcid":false,"given":"Karla","family":"Svobodova","sequence":"additional","affiliation":[{"name":"7Center for Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, Charles University and General University Hospital, Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adela","family":"Berkova","sequence":"additional","affiliation":[{"name":"7Center for Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, Charles University and General University Hospital, Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zuzana","family":"Zemanova","sequence":"additional","affiliation":[{"name":"7Center for Oncocytogenetics, Institute of Medical Biochemistry and Laboratory Diagnostics, Charles University and General University Hospital, Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenka","family":"Daumova","sequence":"additional","affiliation":[{"name":"1Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0316-7290","authenticated-orcid":false,"given":"Vaclav","family":"Herman","sequence":"additional","affiliation":[{"name":"3First Department of Medicine-Department of Hematology, Charles University General Hospital, Prague, Czech Republic"},{"name":"4BIOCEV LF1- Biotechnology and Biomedicine Centre, First Faculty of Medicine, Charles University, Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5982-6523","authenticated-orcid":false,"given":"Alexandra","family":"Doln\u00edkova","sequence":"additional","affiliation":[{"name":"1Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9197-2523","authenticated-orcid":false,"given":"R. Eric","family":"Davis","sequence":"additional","affiliation":[{"name":"8Department of Lymphoma and Myeloma, The UT MD Anderson Cancer Center, Houston, TX"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marek","family":"Trneny","sequence":"additional","affiliation":[{"name":"3First Department of Medicine-Department of Hematology, Charles University General Hospital, Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7786-9378","authenticated-orcid":false,"given":"Pavel","family":"Klener","sequence":"additional","affiliation":[{"name":"1Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic"},{"name":"3First Department of Medicine-Department of Hematology, Charles University General Hospital, Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5826-3557","authenticated-orcid":false,"given":"Ondrej","family":"Havranek","sequence":"additional","affiliation":[{"name":"3First Department of Medicine-Department of Hematology, Charles University General Hospital, Prague, Czech Republic"},{"name":"4BIOCEV LF1- Biotechnology and Biomedicine Centre, First Faculty of Medicine, Charles University, Prague, Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2024,10,10]]},"reference":[{"key":"2024102212453858500_bib1","first-page":"1","article-title":"New directions for mantle cell lymphoma in 2022","volume":"42","author":"Kumar","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"2024102212453858500_bib2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/bjh.17419","article-title":"Mantle cell lymphoma - advances in molecular biology, prognostication and treatment approaches","volume":"195","author":"Silkenstedt","year":"2021","journal-title":"Br J Haematol"},{"issue":"5","key":"2024102212453858500_bib3","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0002-9440(10)65399-0","article-title":"Detection of translocation t(11;14)(q13;q32) in mantle cell lymphoma by fluorescence in situ hybridization","volume":"154","author":"Li","year":"1999","journal-title":"Am J Pathol"},{"issue":"1","key":"2024102212453858500_bib4","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1097\/HS9.0000000000000510","article-title":"Detailed long-term follow-up of patients who relapsed after the nordic mantle cell lymphoma trials: MCL2 and MCL3","volume":"5","author":"Eskelund","year":"2021","journal-title":"Hemasphere"},{"issue":"5","key":"2024102212453858500_bib5","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"issue":"10","key":"2024102212453858500_bib6","doi-asserted-by":"crossref","first-page":"5142","DOI":"10.1182\/blood-2007-07-103481","article-title":"Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma","volume":"111","author":"Dal Col","year":"2008","journal-title":"Blood"},{"issue":"18","key":"2024102212453858500_bib7","doi-asserted-by":"crossref","first-page":"5724","DOI":"10.1158\/1078-0432.CCR-08-3215","article-title":"Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma","volume":"15","author":"Psyrri","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2024102212453858500_bib8","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1182\/blood-2012-10-460832","article-title":"P110\u03b1-mediated constitutive PI3K signaling limits the efficacy of p110\u03b4-selective inhibition in mantle cell lymphoma, particularly with multiple relapse","volume":"121","author":"Iyengar","year":"2013","journal-title":"Blood"},{"key":"2024102212453858500_bib9","doi-asserted-by":"crossref","first-page":"14920","DOI":"10.1038\/ncomms14920","article-title":"Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma","volume":"8","author":"Zhao","year":"2017","journal-title":"Nat Commun"},{"issue":"5","key":"2024102212453858500_bib10","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1158\/1535-7163.MCT-17-0784","article-title":"p110\u03b1 inhibition overcomes stromal cell-mediated ibrutinib resistance in mantle cell lymphoma","volume":"17","author":"Guan","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"2024102212453858500_bib11","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1158\/2159-8290.CD-14-0098","article-title":"Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma","volume":"4","author":"Chiron","year":"2014","journal-title":"Cancer Discov"},{"issue":"10","key":"2024102212453858500_bib12","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/ajh.27044","article-title":"Sequencing-based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy","volume":"98","author":"Karolov\u00e1","year":"2023","journal-title":"Am J Hematol"},{"issue":"16","key":"2024102212453858500_bib13","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1182\/blood-2018-08-867499","article-title":"Parsaclisib, a potent and highly selective PI3K\u03b4 inhibitor, in patients with relapsed or refractory B-cell malignancies","volume":"133","author":"Forero-Torres","year":"2019","journal-title":"Blood"},{"issue":"10020","key":"2024102212453858500_bib14","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet (London, England)"},{"issue":"3","key":"2024102212453858500_bib15","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1097\/HS9.0000000000000398","article-title":"Final results of a phase I\/II trial of the combination bendamustine and rituximab with temsirolimus (BeRT) in relapsed mantle cell lymphoma and follicular lymphoma","volume":"4","author":"Hess","year":"2020","journal-title":"Hemasphere"},{"issue":"1","key":"2024102212453858500_bib16","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.1038\/s41598-023-30148-3","article-title":"Roles of PI3K\u03b3 and PI3K\u03b4 in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3K\u03b3\/\u03b4 inhibitor duvelisib","volume":"13","author":"Till","year":"2023","journal-title":"Sci Rep"},{"issue":"3","key":"2024102212453858500_bib17","doi-asserted-by":"crossref","first-page":"e165694","DOI":"10.1172\/JCI165694","article-title":"Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma","volume":"133","author":"Jiang","year":"2023","journal-title":"J\u00a0Clin Invest"},{"issue":"2","key":"2024102212453858500_bib18","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/bjh.15079","article-title":"Venetoclax as a single agent and in combination with PI3K-MTOR1\/2 kinase inhibitors against ibrutinib sensitive and resistant mantle cell lymphoma","volume":"184","author":"Jiang","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"2024102212453858500_bib19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1158\/1078-0432.CCR-21-2183","article-title":"Phase I\/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring","volume":"28","author":"Stewart","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2024102212453858500_bib20","doi-asserted-by":"crossref","first-page":"102931","DOI":"10.1016\/j.isci.2021.102931","article-title":"The BTK\/PI3K\/BRD4 axis inhibitor SRX3262 overcomes Ibrutinib resistance in mantle cell lymphoma","volume":"24","author":"Pal","year":"2021","journal-title":"iScience"},{"issue":"21","key":"2024102212453858500_bib21","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/blood.V124.21.493.493","article-title":"The B-cell receptor is required for optimal viability, growth, and chemotherapy resistance of diffuse large B-cell lymphoma cell lines of the germinal center B-cell subtype","volume":"124","author":"Havranek","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2024102212453858500_bib22","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-017-0533-9","article-title":"The role of B cell antigen receptors in mantle cell lymphoma","volume":"10","author":"Fichtner","year":"2017","journal-title":"J\u00a0Hematol Oncol"},{"issue":"10","key":"2024102212453858500_bib23","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1002\/cyto.a.24472","article-title":"Detecting F\u00f6rster resonance energy transfer in living cells by conventional and spectral flow cytometry","volume":"101","author":"Henderson","year":"2022","journal-title":"Cytometry"},{"issue":"11","key":"2024102212453858500_bib24","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1038\/s41419-021-04353-9","article-title":"Cooperative miRNA-dependent PTEN regulation drives resistance to BTK inhibition in B-cell lymphoid malignancies","volume":"12","author":"Kapoor","year":"2021","journal-title":"Cell Death Dis"},{"issue":"12","key":"2024102212453858500_bib25","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/s41419-019-2158-0","article-title":"Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K\/AKT activation in B-cell lymphoid malignancies","volume":"10","author":"Kapoor","year":"2019","journal-title":"Cell Death Dis"},{"issue":"20","key":"2024102212453858500_bib26","doi-asserted-by":"crossref","first-page":"11563","DOI":"10.1073\/pnas.201167798","article-title":"Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression","volume":"98","author":"Kwabi-Addo","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2024102212453858500_bib27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2199-2-2","article-title":"Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice","volume":"2","author":"Li","year":"2001","journal-title":"BMC Mol Biol"},{"issue":"3","key":"2024102212453858500_bib28","doi-asserted-by":"crossref","first-page":"E59","DOI":"10.1371\/journal.pbio.0000059","article-title":"Pten dose dictates cancer progression in the prostate","volume":"1","author":"Trotman","year":"2003","journal-title":"PLoS Biol"},{"issue":"12","key":"2024102212453858500_bib29","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.18632\/aging.100855","article-title":"The PTEN tumor suppressor gene and its role in lymphoma pathogenesis","volume":"7","author":"Wang","year":"2015","journal-title":"Aging (Albany NY)"},{"issue":"11","key":"2024102212453858500_bib30","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3390\/biom9110713","article-title":"The mechanisms underlying PTEN loss in human tumors suggest potential therapeutic opportunities","volume":"9","author":"Chang","year":"2019","journal-title":"Biomolecules"},{"issue":"1","key":"2024102212453858500_bib31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1046\/j.1365-2141.2003.04227.x","article-title":"Disparate expression of the PTEN gene: a novel finding in B-cell chronic lymphocytic leukaemia (B-CLL)","volume":"121","author":"Leupin","year":"2003","journal-title":"Br J Haematol"},{"issue":"9","key":"2024102212453858500_bib32","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1073\/pnas.95.9.5246","article-title":"Inactivation of the tumor suppressor PTEN\/MMAC1 in advanced human prostate cancer through loss of expression","volume":"95","author":"Whang","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2024102212453858500_bib33","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nm.4062","article-title":"PTEN opposes negative selection and enables oncogenic transformation of pre-B cells","volume":"22","author":"Shojaee","year":"2016","journal-title":"Nat Med"},{"issue":"1","key":"2024102212453858500_bib34","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1158\/1078-0432.CCR-18-0452","article-title":"Amplification associates with aggressive phenotype but not markers of AKT-MTOR signaling in endometrial carcinoma","volume":"25","author":"Holst","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2024102212453858500_bib35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ccr.2009.04.012","article-title":"AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer","volume":"16","author":"Vasudevan","year":"2009","journal-title":"Cancer Cell"},{"issue":"3","key":"2024102212453858500_bib36","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood-2016-12-758599","article-title":"Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL","volume":"130","author":"Erdmann","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2024102212453858500_bib37","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41588-018-0318-2","article-title":"Molecular landmarks of tumor hypoxia across cancer types","volume":"51","author":"Bhandari","year":"2019","journal-title":"Nat Genet"},{"key":"2024102212453858500_bib38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12935-016-0308-3","article-title":"Hypoxia-induced modulation of PTEN activity and EMT phenotypes in lung cancers","volume":"16","author":"Kohnoh","year":"2016","journal-title":"Cancer Cell Int"},{"key":"2024102212453858500_bib39","doi-asserted-by":"crossref","first-page":"626229","DOI":"10.3389\/fcell.2021.626229","article-title":"Tumor hypoxia drives genomic instability","volume":"9","author":"Tang","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"2024102212453858500_bib40","doi-asserted-by":"crossref","first-page":"613114","DOI":"10.3389\/fimmu.2020.613114","article-title":"Tumor hypoxia regulates immune escape\/invasion: influence on angiogenesis and potential impact of hypoxic biomarkers on cancer therapies","volume":"11","author":"Abou Khouzam","year":"2020","journal-title":"Front Immunol"},{"issue":"4","key":"2024102212453858500_bib41","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1101\/gad.14.4.391","article-title":"Loss of PTEN facilitates HIF-1-mediated gene expression","volume":"14","author":"Zundel","year":"2000","journal-title":"Genes Dev"},{"key":"2024102212453858500_bib42","doi-asserted-by":"crossref","first-page":"556","DOI":"10.3389\/fonc.2018.00556","article-title":"Metabolic reprogramming of non-Hodgkin's B-cell lymphomas and potential therapeutic strategies","volume":"8","author":"Ricci","year":"2018","journal-title":"Front Oncol"},{"key":"2024102212453858500_bib43","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3389\/fendo.2018.00129","article-title":"The role for Myc in coordinating glycolysis, oxidative phosphorylation, glutaminolysis, and fatty acid metabolism in normal and neoplastic tissues","volume":"9","author":"Goetzman","year":"2018","journal-title":"Front Endocrinol"},{"key":"2024102212453858500_bib44","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-3-319-42118-6_3","article-title":"Metabolic reprogramming by the PI3K-Akt-mTOR pathway in cancer","volume":"207","author":"Lien","year":"2016","journal-title":"Recent Results Cancer Res"},{"issue":"3","key":"2024102212453858500_bib45","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cell.2015.12.042","article-title":"Phosphoinositide 3-kinase regulates glycolysis through mobilization of aldolase from the actin cytoskeleton","volume":"164","author":"Hu","year":"2016","journal-title":"Cell"},{"issue":"11","key":"2024102212453858500_bib46","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1158\/0008-5472.CAN-03-2904","article-title":"Akt stimulates aerobic glycolysis in cancer cells","volume":"64","author":"Elstrom","year":"2004","journal-title":"Cancer Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/20\/5279\/2247396\/blooda_adv-2024-013205-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/20\/5279\/2247396\/blooda_adv-2024-013205-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T08:46:02Z","timestamp":1729586762000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/20\/5279\/517397\/Impact-of-PIK3CA-gain-and-PTEN-loss-on-mantle-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,10]]},"references-count":46,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2024,10,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013205","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.04.30.591749","asserted-by":"object"}]},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,10]]}}}